News

Zurich/Lugano - The start-up platform Hoop has reported the first fully digital company foundation in Switzerland. In partnership with the IT service provider DeepCloud and the new digital bank Yapeal, this process was completed in just six hours. After a soft launch for 20 trustees, all interested parties should be able to take advantage of this service from June.

Zurich - A team from the Swiss Federal Institute of Technology in Zurich (ETH) has examined the interactions between human cells and their natural environment. The focus of this research was on influencing factors behind cell growth. The findings should now help in the development of new cancer treatments.

Zug - SHL Medical is developing an autoinjector for MoonLake Immunotherapeutics. This is intended to secure the clinical and potential commercial supply of MoonLake’s drug candidate sonelokimab, a nanobody technology for the treatment of inflammatory diseases such as psoriasis.

Zug - Aphaia Pharma has dosed the first patient in a phase 2 trial evaluating its lead candidate for prediabetes. APH-012 is expected to improve glucose tolerance in patients with this condition.

Zurich - Helbling helps companies improve the usability of industrial tools and business applications. The result is user interfaces of devices, machines and systems that can be operated more intuitively. This increases employees’ efficiency and motivation.

Zurich - Researchers from the Swiss Federal Institute of Technology in Zurich and University Hospital Zurich have a new method at their disposal to predict the best possible treatment approach for all multiple myeloma patients. This form of blood cancer remains incurable and often returns despite treatment.

Schaffhausen - The driverless electric bus used on STL Line 13 has officially taken to the roads of Schaffhausen. This is Switzerland’s first dual mode technology bus. The project is the brainchild of the Swiss Transit Lab mobility initiative.

Zurich - An international research team including scientists from the University of Zurich has discovered that rare kidney cells produce the vital hormone EPO. This harbors great medical potential for people with chronic kidney disease due, for example, to the fact that EPO deficiency can lead to anemia, or in severe cases to death.

Deitingen/Zurich - Megasol Energie AG has been named as the winner of the Export Award 2023 presented by Switzerland Global Enterprise. The export share of the manufacturer of solar modules and smart installation systems now stands at 85 percent. Dagsmejan and Stratron also made the final.